Genetic regulation on ex vivo differentiated natural killer cells from human umbilical cord blood CD34+ cells

Journal of Receptors and Signal Transduction

Volumn 32, Issue 5, 2012, Pages 238-249

  Pinho, Maria João ^a   Marques, Cristina Joana ^a   Carvalho, Filipa ^a   Punzel, Michael ^b   Sousa, Mário ^a,c   Barros, Alberto ^a  

^a University of Porto   (Portugal)

^b Center for Bone Marrow and Stem Cell Donation   (Germany)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

NK cell ontogeny; NK cell receptors; Transcription factors

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD135 ANTIGEN; CD34 ANTIGEN; CELL MARKER; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; IKAROS TRANSCRIPTION FACTOR; INHIBITOR OF DIFFERENTIATION 2; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 7; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E4BP4; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; DOWN REGULATION; EX VIVO STUDY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; ONTOGENY; PROTEIN EXPRESSION; UMBILICAL CORD BLOOD;

ANIMALS; ANTIGENS, CD34; CELL DIFFERENTIATION; FETAL BLOOD; GENE EXPRESSION REGULATION; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MICE; RECEPTORS, NATURAL KILLER CELL; RNA, MESSENGER; TRANSCRIPTION FACTORS;

MUS;

EID: 84866626199     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2012.700716     Document Type: Article

References (53)

1. Di Santo JP. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006, 24, 257-286.
2. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006, 20, 123-137.
3. Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res 2001, 10, 369-383.
4. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versusleukemia effect. Blood 2002, 100, 1935-1947.
5. Moretta A, Bottino C, Sivori S, Marcenaro E, Castriconi R, Della Chiesa M, Carlomagno S, Augugliaro R, Nanni M, Vitale M, Millo R. Natural killer lymphocytes: "null cells" no more. Ital J Anat Embryol 2001, 106, 335-342.
6. Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14, 123-133.
7. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11, 237-244.
8. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997, 91, 661-672.
9. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995, 3, 459-473.
10. Vosshenrich CA, Samson-Villéger SI, Di Santo JP. Distinguishing features of developing natural killer cells. Curr Opin Immunol 2005, 17, 151-158.
11. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol 2003, 3, 413-425.
12. Kim S, Iizuka K, Kang HS, Dokun A, French AR, Greco S, Yokoyama WM. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol 2002, 3, 523-528.
13. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005, 22, 295-304.
14. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006, 203, 1033-1043.
15. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev 2006, 214, 56-72.
16. Mujaj SASMM, Gandhi MK, Nourse JP. Molecular mechanisms influencing NK cell development: implications for NK cell malignancies. Am J Blood Res 2011;1:34-45.
17. Warren LA, Rothenberg EV. Regulatory coding of lymphoid lineage choice by hematopoietic transcription factors. Curr Opin Immunol 2003, 15, 166-175.
18. Singh H, Medina KL, Pongubala JM. Contingent gene regulatory networks and B cell fate specification. Proc Natl Acad Sci USA 2005, 102, 4949-4953.
19. Boggs SS, Trevisan M, Patrene K, Geogopoulos K. Lack of natural killer cell precursors in fetal liver of Ikaros knockout mutant mice. Nat Immun 1998, 16, 137-145.
20. Barton K, Muthusamy N, Fischer C, Ting CN, Walunas TL, Lanier LL, Leiden JM. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 1998, 9, 555-563.
21. Colucci F, Di Santo JP. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. Blood 2000, 95, 984-991.
22. DeKoter RP, Lee HJ, Singh H. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity 2002, 16, 297-309.
23. Samson SI, Richard O, Tavian M, Ranson T, Vosshenrich CA, Colucci F, Buer J, Grosveld F, Godin I, Di Santo JP. GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity 2003, 19, 701-711.
24. Townsend MJ, Weinmann AS, Matsuda JL, Salomon R, Farnham PJ, Biron CA, Gapin L, Glimcher LH. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004, 20, 477-494.
25. Lohoff M, Duncan GS, Ferrick D, Mittrücker HW, Bischof S, Prechtl S, Röllinghoff M, Schmitt E, Pahl A, Mak TW. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J Exp Med 2000, 192, 325-336.
26. Lian RH, Kumar V. Murine natural killer cell progenitors and their requirements for development. Semin Immunol 2002, 14, 453-460.
27. Taki S, Nakajima S, Ichikawa E, Saito T, Hida S. IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells. J Immunol 2005, 174, 6005-6012.
28. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, Cereb N, Yao TP, Yang SY, Reiner SL. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001, 292, 1907-1910.
29. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kündig TM, Amakawa R, Kishihara K, Wakeham A. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993, 75, 83-97.
30. Marusina AI, Kim DK, Lieto LD, Borrego F, Coligan JE. GATA-3 is an important transcription factor for regulating human NKG2A gene expression. J Immunol 2005, 174, 2152-2159.
31. Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, Cordon-Cardo C, Mao S, Pandolfi PP, Nimer SD. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 2002, 17, 437-449.
32. Engel I, Murre C. The function of E- and Id proteins in lymphocyte development. Nat Rev Immunol 2001, 1, 193-199.
33. Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa S, Gruss P. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999, 397, 702-706.
34. Ikawa T, Fujimoto S, Kawamoto H, Katsura Y, Yokota Y. Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc Natl Acad Sci USA 2001, 98, 5164-5169.
35. Aliahmad P, de la Torre B, Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissueinducer cell and NK cell lineages. Nat Immunol 2010, 11, 945-952.
36. Kamizono S, Duncan GS, Seidel MG, Morimoto A, Hamada K, Grosveld G, Akashi K, Lind EF, Haight JP, Ohashi PS, Look AT, Mak TW. Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med 2009, 206, 2977-2986.
37. Gascoyne DM, Long E, Veiga-Fernandes H, de Boer J, Williams O, Seddon B, Coles M, Kioussis D, Brady HJ. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 2009, 10, 1118-1124.
38. Hu T, Gimferrer I, Simmons A, Wiest D, Alberola-Ila J. The Ras/ MAPK pathway is required for generation of iNKT cells. PLoS ONE 2011, 6, e19890.
39. Smith MA, Maurin M, Cho HI, Becknell B, Freud AG, Yu J, Wei S, Djeu J, Celis E, Caligiuri MA, Wright KL. PRDM1/Blimp-1 controls effector cytokine production in human NK cells. J Immunol 2010, 185, 6058-6067.
40. Kallies A, Carotta S, Huntington ND, Bernard NJ, Tarlinton DM, Smyth MJ, Nutt SL. A role for Blimp1 in the transcriptional network controlling natural killer cell maturation. Blood 2011, 117, 1869-1879.
41. Li P, Burke S, Wang J, Chen X, Ortiz M, Lee SC, Lu D, Campos L, Goulding D, Ng BL, Dougan G, Huntly B, Gottgens B, Jenkins NA, Copeland NG, Colucci F, Liu P. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science 2010, 329, 85-89.
42. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295, 2097-2100.
43. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285, 412-415.
44. Pinho MJ, Punzel M, Sousa M, Barros A. Ex vivo differentiation of natural killer cells from human umbilical cord blood CD34+ progenitor cells. Cell Commun Adhes 2011, 18, 45-55.
45. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402-408.
46. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002, 30, e36.
47. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007, 7, 703-714.
48. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998, 187, 2065-2072.
49. Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, Groner Y, Rao A. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 2009, 206, 51-59.
50. Boos MD, Yokota Y, Eberl G, Kee BL. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2- mediated suppression of E protein activity. J Exp Med 2007, 204, 1119-1130.
51. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002, 13, 169-183.
52. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105, 3051-3057.
53. Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011, 2011, 379123.